Our failure is also consistent with data from melanoma where we had identified that engraftment of DCCs requires activation of specific oncogenic pathways55—which in case of PIK3CA mutations early (M0-stage) breast cancer DCCs commonly lack. This evidence concerns the gene PIK3CA and breast carcinoma.